The drug’s journey towards clinical validation has seen significant progress, with approval for Phase I clinical trials in both the US and Korea. SN Bioscience is now poised to submit investigational new drug (IND) applications for Phase II trials in the US and Europe, following encouraging results in pancreatic cancer animal models.
Furthermore, SNB-101’s designation as an orphan drug by the US FDA underscores its potential as a therapeutic breakthrough. This designation provides exclusive marketing rights, tax credits, trial design assistance, and exemption from review application fees, offering significant incentives for its accelerated clinical development.
Despite these advancements, the pharmaceutical landscape faces legislative debates surrounding drug pricing and innovation. US lawmakers in the House of Representatives are deliberating changes to the Inflation Reduction Act (IRA), particularly focusing on the bipartisan Optimizing Research Progress Hope And New (ORPHAN) Cures Act and Maintaining Investments in New Innovation (MINI) Act.
The ORPHAN Cures Act proposes exemptions for orphan drugs exclusively approved for rare diseases, aiming to streamline negotiations. Conversely, the MINI Act seeks to delay negotiations for certain “advanced drug products.” However, concerns have been raised regarding the potential impact of these amendments on innovation within the pharmaceutical industry.
While some argue that the IRA may stifle innovation, others contend that the legislation will ensure access to affordable cures while preserving innovation. The ongoing debate highlights the complexities surrounding drug pricing and regulatory frameworks, with stakeholders advocating for policies that balance access, affordability, and innovation.
As SN Bioscience advances the clinical development of SNB-101, its potential to revolutionize cancer treatment underscores the importance of fostering an environment conducive to innovation within the pharmaceutical industry. Amidst legislative discussions, the pursuit of groundbreaking therapies like SNB-101 remains pivotal in addressing unmet medical needs and improving patient outcomes.
https://www.pharmaceutical-business-review.com/news/sn-bioscience-fda-orphan-drug/
https://endpts.com/house-committee-debates-ira-changes-that-would-impact-orphan-drugs-and-other-areas/
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services